P. Bishop, K. Rao, V. Wilson, and W. , Burkitt's Lymphoma: Molecular Pathogenesis and Treatment, Cancer Investigation, vol.92, issue.6, pp.574-83, 2000.
DOI : 10.1007/BF01797862

M. Diviné, E. Lepage, and J. Brière, Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte., Journal of Clinical Oncology, vol.14, issue.1, pp.240-288, 1996.
DOI : 10.1200/JCO.1996.14.1.240

D. Longo, P. Duff-ey, and E. Jaff-e, Diff use small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to proMACE-based combination chemotherapy

L. Jost, J. E. Dommann-scherrer, and C. , Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients, Annals of Oncology, vol.6, issue.5, pp.445-51, 1995.
DOI : 10.1093/oxfordjournals.annonc.a059214

C. Patte, T. Philip, and C. Rodary, Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society., Journal of Clinical Oncology, vol.4, issue.8, pp.1219-1245, 1986.
DOI : 10.1200/JCO.1986.4.8.1219

C. Patte, T. Philip, and C. Rodary, High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children., Journal of Clinical Oncology, vol.9, issue.1, pp.123-155, 1991.
DOI : 10.1200/JCO.1991.9.1.123

C. Patte, A. Auperin, and J. Michon, The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia, Blood, vol.97, issue.11, pp.3370-79, 2001.
DOI : 10.1182/blood.V97.11.3370

M. Cairo, M. Gerrard, and R. Sposto, Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents, Blood, vol.109, pp.2736-2779, 2007.

C. Patte, A. Auperin, and M. Gerrard, of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients, Blood, vol.109, pp.2773-80, 2007.

M. Diviné, P. Casassus, and S. Koscielny, Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol, Annals of Oncology, vol.16, issue.12, pp.1928-1963, 2005.
DOI : 10.1093/annonc/mdi403

D. Thomas, J. Cortes, O. Brien, and S. , Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia, Journal of Clinical Oncology, vol.17, issue.8, pp.2461-70, 1999.
DOI : 10.1200/JCO.1999.17.8.2461

I. Magrath, M. Adde, and A. Shad, Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen., Journal of Clinical Oncology, vol.14, issue.3, pp.925-959, 1996.
DOI : 10.1200/JCO.1996.14.3.925

A. Petroni, G. Schiff-er, and C. , Brief-duration high-intensity chemotherapy for patients with small-non cleaved lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251, J Clin Oncol, vol.19, pp.4014-4036, 2001.

T. Intermesoli, A. Rambaldi, and G. Rossi, High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program, Haematologica, vol.98, issue.11, pp.1718-1743, 2013.
DOI : 10.3324/haematol.2013.086827

K. Dunleavy, S. Pittaluga, and M. Shovlin, Low-Intensity Therapy in Adults with Burkitt's Lymphoma, New England Journal of Medicine, vol.369, issue.20, pp.1915-1940, 2013.
DOI : 10.1056/NEJMoa1308392

S. Goldman, L. Smith, and P. Galardy, Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report, British Journal of Haematology, vol.105, issue.3, pp.394-401, 2014.
DOI : 10.1111/bjh.13040

E. B. Coiffi, E. Lepage, and J. Briere, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-277, 2002.
DOI : 10.1056/NEJMoa011795

E. Jaff-e, N. Harris, H. Stein, and J. Vardiman, World Health Organization classifi cation of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues, International Agency for Research on Cancer Press, pp.181-84, 2001.

S. Swerdlow, E. Campo, and N. Harris, WHO classifi cation of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer, 2008.

S. Murphy, Classifi cation, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults, Semin Oncol, vol.7, pp.332-371, 1980.

B. Cheson, S. Horning, and B. Coiffi-er, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

D. Machin, M. Campbell, P. Fayers, and A. Pinol, Sample size tables for clinical studies, Oxford: Blackwell Science, p.251, 1997.
DOI : 10.1002/9781444300710

G. Mead, M. Sydes, and J. Welewski, An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study, Annals of Oncology, vol.13, issue.8, pp.1264-74, 2002.
DOI : 10.1093/annonc/mdf253

G. Todeschini, M. Bonifacio, and C. Tecchio, Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia, American Journal of Hematology, vol.106, issue.1, pp.22-25, 2012.
DOI : 10.1002/ajh.22189

G. Mead, S. Barrans, and W. Qian, A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial), Blood, vol.112, issue.6, pp.2248-60, 2008.
DOI : 10.1182/blood-2008-03-145128

D. Rizzieri, J. Johnson, and J. Byrd, Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10??002, British Journal of Haematology, vol.29, issue.1, pp.102-113, 2014.
DOI : 10.1111/bjh.12736

D. Hoelzer, J. Walewski, and H. Döhner, Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial, Blood, vol.124, issue.26, pp.3870-79, 2014.
DOI : 10.1182/blood-2014-03-563627

D. Thomas, O. Brien, S. Faderl, and S. , Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia, Cancer, vol.23, issue.7, pp.1569-80, 2006.
DOI : 10.1002/cncr.21776

G. Corazzelli, F. Frigeri, and F. Russo, RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifi able' highly aggressive B-cell lymphoma
DOI : 10.1111/j.1365-2141.2011.08947.x

J. Barnes, A. Lacasce, and Y. Feng, Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis, Annals of Oncology, vol.22, issue.8, pp.1859-64, 2011.
DOI : 10.1093/annonc/mdq677